

### Amendments to the Claims

The listing of claims below is intended to replace all prior listings of claims presented in the above-identified application.

1. (Currently amended) A method of ~~preventing or~~ treating Alzheimer's Disease in a subject comprising:

administering to the subject an agent ~~which~~, wherein the agent (1) binds to a site of apolipoprotein E that binds to SEQ ID NO:4, and (2) inhibits interaction between amyloid- $\beta$  peptide and apolipoprotein E, compared to when the agent is absent, to ~~prevent or~~ treat Alzheimer's Disease in the subject.

2-3 (Canceled)

4. (Previously presented) The method according to claim 1, wherein the agent is a protein or a peptidomimetic.

5. (Original) The method according to claim 4, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4.

6. (Canceled)

7. (Original) The method according to claim 1, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

8. (Original) The method according to claim 1, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

9. (Original) The method according to claim 1, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

10. (Canceled)

11. (Canceled)

12. (Currently amended) A method of inhibiting accumulation of amyloid- $\beta$  peptide deposits in a subject's brain comprising:

administering to the subject an agent ~~which~~, wherein the agent (1) binds to a site of apolipoprotein E that binds to SEQ ID NO:4, and (2) inhibits interaction between amyloid- $\beta$  peptide and apolipoprotein E, compared to when the agent is absent, to inhibit accumulation of amyloid- $\beta$  peptide deposits in the subject's brain.

13-14 (Canceled)

15. (Original) The method according to claim 12, wherein the agent is a protein or a peptidomimetic.

16. (Original) The method according to claim 15, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 2 or 3.

17. (Canceled)

18. (Original) The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NOs: 3 or 4.

19. (Original) The method according to claim 12, wherein the agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

20. (Original) The method according to claim 12, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

21-26. (Canceled)